Bristol-Myers Squibb reports four-year follow-up data from phase 3 ELOQUENT-2 study
Bristol-Myers Squibb reported four-year follow-up data from the Phase 3 ELOQUENT-2 study in which Empliciti (elotuzumab) plus lenalidomide/dexamethasone continued to demonstrate efficacy in patients with RRMM, compared to patients treated with Ld alone. June 24, 2017